To undertake a retrospective review of patients with SLE who had received Rituximab in order to determine the rates and associated patient characteristics of clinically significant adverse infusion reactions. A descriptive analysis was undertaken of each infusion reaction, which was then assessed using the clinical information available to hypothesise on the possible underlying mechanism(s). Records of 136 SLE patients previously treated with 481 individual infusions of Rituximab were reviewed. A total of 22 patients (17.6%) had 28 (5.8% of total infusions) documented clinically significant adverse infusion reactions. Average age at first Rituximab infusion in patients without a reaction was 37 years (range 16–73) compared with 30 years (range 18–56) in those with a reaction. A high proportion of men (18.2%) experienced an infusion reaction. Severity and type of reaction varied. 6.4% of those who had a reaction were not retreated. While Rituximab remains an important tool in the treatment of SLE it is important to be aware that rates of infusion reactions may be more significant in SLE than in other diseases. A prospective study is required to better characterise the reactions.

中文翻译：

---

系统性红斑狼疮对利妥昔单抗的不良输注反应：回顾性分析

对接受利妥昔单抗治疗的 SLE 患者进行回顾性审查，以确定临床显着的输液不良反应的发生率和相关患者特征。对每个输注反应进行描述性分析，然后使用可用于假设可能的潜在机制的临床信息进行评估。回顾了先前接受过 481 次利妥昔单抗单独输注治疗的 136 名 SLE 患者的记录。共有 22 名患者（17.6%）有 28 名（占总输注的 5.8%）记录在临床上显着的输注不良反应。没有反应的患者首次输注利妥昔单抗的平均年龄为 37 岁（范围 16-73），而有反应的患者为 30 岁（范围 18-56）。高比例的男性（18.2%）经历了输液反应。反应的严重程度和类型各不相同。6.4%有反应的人没有撤退。虽然利妥昔单抗仍然是治疗 SLE 的重要工具，但重要的是要意识到 SLE 的输液反应率可能比其他疾病更重要。需要一项前瞻性研究来更好地描述这些反应。